Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 27 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMAGEST BELGIUM from Charleroi, company number BE0476626524, closed financial year 2025 with a result of € -86,260 after tax. For that financial year PHARMAGEST BELGIUM recorded a gross margin of € 1.5 million and equity of € -2.8 million. Compared with financial year 2024, the result moved from € -375,573 to € -86,260. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 5, 2026.
€ -2.8 million
▼ € 86,260 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -86,260
▲ 77 % less loss than in 2024
Profit after tax over the fiscal year.
€ 179,201
▼ 6% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.9 million.
People and assets in 2025
19.6
▲ 0.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.4 million
€ 72,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 54,110
▼ 41% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 268,099
▲ 18% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 255,734
▲ 25% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,018,198 | € 1,138,798 | € 1,137,256 | € 1,511,254 | ▲ 33% |
| Profit after taxes | € -382,384 | € -459,603 | € -375,573 | € -86,260 | ▲ € 289,313 |
| Equity | € -1,926,782 | € -2,386,385 | € -2,761,957 | € -2,848,217 | ▼ € 86,260 |
| Total debts | € 2,826,676 | € 2,935,877 | € 3,511,521 | € 3,985,541 | ▲ 13% |
| Cash | € 133,370 | € 101,207 | € 191,175 | € 179,201 | ▼ 6% |
| Retained profit | € -1,945,382 | € -2,404,985 | € -2,780,557 | € -2,866,817 | ▼ € 86,260 |
| Bank debt | € 100,600 | € 50,451 | € 0 | € 0 | |
| Balance sheet total | € 1,025,201 | € 673,097 | € 751,219 | € 1,139,740 | ▲ 52% |
| Employees (FTE) | 20.7 | 20.1 | 18.7 | 19.6 | ▲ 0.9 |
Key figures of PHARMAGEST BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMAGEST BELGIUM?
What happened at PHARMAGEST BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 86,260. filed late Source: NBB ↗
- Denis SUPPLISSON became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 382,384 loss in 2022 to € 86,260 loss in 2025.
Paid € 16,981 in corporate taxes since 2022.
On average € 77,100 of value added per employee in 2025.
A new publication or filing at PHARMAGEST BELGIUM? We notify you, reason included.
Follow PHARMAGEST BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMAGEST BELGIUM is Denis SUPPLISSON.
Directors
According to the 2025 annual accounts
Denis SUPPLISSON
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Avenue Georges Lemaitre 58 box B
6041 Charleroi
Avenue Georges Lemaitre 58 box b
6041 Charleroi
Active since 7 June 2002
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
AS-EQUASENS-PHARMAGEST, FR
Website info
Features
Security
Details
- Company number
- 0476.626.524
- VAT number
- BE 0476.626.524
- Registered office
- Avenue Georges Lemaitre 58 bus B, 6041 Charleroi
- Names & denominations
- PHARMAGEST BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 January 2002
- Peppol
- Active · Active since 15 Dec 2025
- Contact
- pharmagest.be
- Activities · NACE
Groothandel in informatie- en communicatieapparatuur
Groothandel in computers, randapparatuur en programmatuur
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computeradviesbureaus
Groothandel in computers, randapparatuur en software
Computerconsultancy-activiteiten
Overige diensten op het gebied van informatietechnologie en computer
Ontwerpen van computerprogramma’s
+3